South Dakota Investment Council boosted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 37.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,700 shares of the medical instruments supplier’s stock after purchasing an additional 5,900 shares during the period. South Dakota Investment Council owned approximately 0.06% of AngioDynamics worth $427,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Northern Trust Corp increased its holdings in AngioDynamics by 1.0% in the 2nd quarter. Northern Trust Corp now owns 1,179,665 shares of the medical instruments supplier’s stock valued at $23,228,000 after purchasing an additional 11,387 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of AngioDynamics by 0.8% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 651,319 shares of the medical instruments supplier’s stock valued at $12,824,000 after acquiring an additional 5,000 shares in the last quarter. Fenimore Asset Management Inc. grew its stake in shares of AngioDynamics by 0.5% during the second quarter. Fenimore Asset Management Inc. now owns 571,100 shares of the medical instruments supplier’s stock valued at $11,245,000 after acquiring an additional 2,800 shares in the last quarter. Systematic Financial Management LP grew its stake in shares of AngioDynamics by 586.4% during the second quarter. Systematic Financial Management LP now owns 380,622 shares of the medical instruments supplier’s stock valued at $7,494,000 after acquiring an additional 325,172 shares in the last quarter. Finally, Kennedy Capital Management Inc. grew its stake in shares of AngioDynamics by 4.2% during the first quarter. Kennedy Capital Management Inc. now owns 357,852 shares of the medical instruments supplier’s stock valued at $8,180,000 after acquiring an additional 14,448 shares in the last quarter. Hedge funds and other institutional investors own 99.51% of the company’s stock.

Shares of ANGO stock traded up $0.21 during trading hours on Friday, hitting $18.60. 13,353 shares of the company were exchanged, compared to its average volume of 139,695. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.75 and a current ratio of 4.30. AngioDynamics, Inc. has a one year low of $17.67 and a one year high of $25.48. The business’s 50-day simple moving average is $19.22 and its two-hundred day simple moving average is $20.45. The stock has a market capitalization of $679.65 million, a price-to-earnings ratio of 22.27 and a beta of 0.72.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.01). AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The company had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. During the same period in the previous year, the business posted $0.20 EPS. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. As a group, analysts anticipate that AngioDynamics, Inc. will post 0.27 EPS for the current fiscal year.

In other news, Director Kevin J. Gould sold 13,650 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $21.45, for a total transaction of $292,792.50. Following the transaction, the director now owns 61,774 shares of the company’s stock, valued at $1,325,052.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.60% of the company’s stock.

Several analysts have recently weighed in on ANGO shares. TheStreet downgraded AngioDynamics from a “b” rating to a “c” rating in a research note on Monday, July 29th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating and set a $20.00 target price for the company in a research note on Tuesday, June 4th. BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research note on Saturday, August 31st. Finally, ValuEngine upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. AngioDynamics presently has an average rating of “Hold” and an average target price of $21.50.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.